Lupin-led arm launches Luforbec for asthma and COPD treatment in UK

Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US.

Aug 24, 2021 04:08 IST India Infoline News Service

Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), on Tuesday has announced that following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, it has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.

Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal).

Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US.

In the twelve months to May 2021, the NHS spent over £177 million on Fostair 100/6 pMDI.

Luforbec is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA)) is appropriate. This includes patients not adequately controlled with ICS and ‘as needed’ inhaled short-acting beta2-agonist or patients already adequately controlled on both ICS and LABA.

Lupin ended at Rs940.90 per piece up by Rs16.15 or 1.75% on Sensex.

Related Story

Open Free Demat Account (Rs699)